UCB Signs Pacts In Neuroscience | Chemical & Engineering News
 
 
0
Facebook
Volume 91 Issue 9 | p. 23 | Concentrates
Issue Date: March 4, 2013

UCB Signs Pacts In Neuroscience

Department: Business
Keywords: neuroscience, collaboration, receptors, GPCR

Belgian drugmaker UCB has joined with two biotech firms in the neuroscience area. It will work for two years with California-based ConfometRx on drugs that modulate G protein-coupled receptor targets. As the largest family of signaling proteins, GPCRs are involved in most physiological processes. In another deal, UCB will pay a $20 million licensing fee and additional milestone fees for exclusive rights to Biotie’s tozadenant. The Finnish firm . . .

You Do Not Have Access to C&EN Protected Content.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society